Tanya Siddiqi Selected Research

Brentuximab Vedotin

1/2019	A phase 2, open-label study of brentuximab vedotin in patients with CD30-expressing solid tumors.
1/2017	Brentuximab vedotin activity in diffuse large B-cell lymphoma with CD30 undetectable by visual assessment of conventional immunohistochemistry.
12/2015	Results of a Multicenter Phase II Trial of Brentuximab Vedotin as Second-Line Therapy before Autologous Transplantation in Relapsed/Refractory Hodgkin Lymphoma.
11/2014	Brentuximab vedotin is associated with improved progression-free survival after allogeneic transplantation for Hodgkin lymphoma.
5/2014	Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin.
1/2014	Role of brentuximab vedotin in the treatment of relapsed or refractory Hodgkin lymphoma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Tanya Siddiqi Research Topics

Disease

21	Neoplasms (Cancer) 01/2024 - 01/2014
19	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 04/2024 - 03/2015
14	Lymphoma (Lymphomas) 01/2024 - 05/2014
9	B-Cell Lymphoma (Lymphoma, B Cell) 04/2024 - 12/2017
7	Non-Hodgkin Lymphoma (Lymphosarcoma) 10/2021 - 03/2015
5	Waldenstrom Macroglobulinemia (Macroglobulinemia) 02/2024 - 10/2020
5	Residual Neoplasm 01/2024 - 01/2018
5	Disease Progression 01/2023 - 03/2015
5	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 12/2022 - 01/2017
4	Neutropenia 11/2023 - 05/2014
4	Hodgkin Disease (Hodgkin's Disease) 10/2022 - 01/2014
4	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 01/2022 - 03/2015
3	Atrial Fibrillation 11/2023 - 10/2020
3	Diarrhea 11/2023 - 12/2015
3	Leukemia 01/2022 - 12/2017
3	Hemorrhage 12/2020 - 12/2015
2	Spasm (Spasms) 11/2023 - 10/2020
2	Hypertension (High Blood Pressure) 11/2023 - 12/2020
2	Pneumonia (Pneumonitis) 11/2023 - 10/2020
2	Tumor Lysis Syndrome 01/2022 - 12/2021
2	Cytokine Release Syndrome 01/2021 - 01/2017
2	Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular) 01/2019 - 12/2017
2	Pathologic Complete Response 12/2015 - 10/2008
1	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/2024
1	COVID-19 12/2023
1	Hematologic Neoplasms (Hematological Malignancy) 01/2023
1	Musculoskeletal Pain 01/2022
1	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 01/2022
1	Myalgia 01/2022
1	Arthralgia (Joint Pain) 01/2022
1	Graft vs Host Disease (Graft-Versus-Host Disease) 01/2022
1	Central Nervous System Diseases (CNS Diseases) 01/2021
1	Autoimmune Diseases (Autoimmune Disease) 01/2021
1	Infections 10/2020
1	Edema (Dropsy) 10/2020
1	Contusions 10/2020
1	Multiple Myeloma 10/2020
1	Hairy Cell Leukemia 01/2018
1	Peripheral Nervous System Diseases (PNS Diseases) 01/2018

Drug/Important Bio-Agent (IBA)

15	ibrutinibIBA 02/2024 - 12/2015
8	axicabtagene ciloleucelIBA 04/2024 - 01/2017
8	Chimeric Antigen ReceptorsIBA 04/2024 - 12/2017
7	Agammaglobulinaemia Tyrosine KinaseIBA 02/2024 - 10/2016
7	venetoclaxIBA 01/2024 - 12/2021
6	Brentuximab VedotinIBA 01/2019 - 01/2014
5	Rituximab (Mabthera)FDA Link 12/2022 - 10/2008
4	zanubrutinibIBA 02/2024 - 10/2020
4	Monoclonal AntibodiesIBA 01/2021 - 01/2014
3	Messenger RNA (mRNA)IBA 12/2023 - 01/2018
3	Cyclophosphamide (Cytoxan)FDA LinkGeneric 12/2022 - 12/2017
3	Immunoconjugates (Immunoconjugate)IBA 01/2019 - 01/2014
2	fludarabineIBA 01/2022 - 12/2017
2	AntigensIBA 01/2021 - 01/2019
2	Vorinostat FDA Link 01/2020 - 03/2015
2	umbralisibIBA 11/2019 - 02/2019
2	ublituximabIBA 11/2019 - 02/2019
2	AnticoagulantsIBA 11/2018 - 09/2015
2	Bortezomib (Velcade)FDA Link 01/2018 - 10/2008
1	Immunoglobulin Heavy Chains (Immunoglobulin Heavy Chain)IBA 04/2024
1	Biomarkers (Surrogate Marker)IBA 02/2024
1	Bispecific AntibodiesIBA 01/2024
1	COVID-19 VaccinesIBA 12/2023
1	mRNA VaccinesIBA 12/2023
1	VaccinesIBA 12/2023
1	pevonedistatIBA 01/2023
1	RNA Splicing FactorsIBA 01/2023
1	Antigen-Antibody Complex (Immune Complex)IBA 01/2023
1	Enzyme Inhibitors (Inhibitors, Enzyme)IBA 01/2023
1	EnzymesIBA 01/2023
1	InterferonsIBA 01/2023
1	ChemokinesIBA 01/2023
1	Small Cytoplasmic RNAIBA 01/2023
1	Doxorubicin (Adriamycin)FDA LinkGeneric 12/2022
1	polatuzumab vedotinIBA 12/2022
1	Vincristine (Oncovin)FDA LinkGeneric 12/2022
1	Prednisone (Sone)FDA LinkGeneric 12/2022
1	Immune Checkpoint InhibitorsIBA 12/2022
1	Programmed Cell Death 1 ReceptorIBA 12/2022
1	avelumabIBA 10/2022
1	Tumor Viral Antigens (Large T Antigen)IBA 01/2022
1	Phosphotransferases (Kinase)IBA 01/2021
1	BI 836826IBA 01/2021
1	Enoxaparin (Lovenox)FDA LinkGeneric 12/2020
1	Metformin (Glucophage)FDA LinkGeneric 10/2020
1	Ritonavir (Norvir)FDA Link 10/2020
1	Aurora Kinase AIBA 01/2020
1	Histone Deacetylase InhibitorsIBA 01/2020
1	MLN 8237IBA 01/2020
1	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 11/2019
1	Proteins (Proteins, Gene)FDA Link 11/2019
1	AnthracyclinesIBA 01/2019
1	immunotoxin HA22IBA 01/2018

Therapy/Procedure

27	Therapeutics 04/2024 - 03/2015
6	Drug Therapy (Chemotherapy) 10/2021 - 01/2014
6	Stem Cell Transplantation 01/2019 - 01/2014
3	Cell Transplantation 01/2022 - 11/2014
2	Immunotherapy 01/2024 - 01/2023
2	Combination Drug Therapy (Combination Chemotherapy) 12/2015 - 01/2014
1	Intravenous Infusions 01/2023
1	Cell- and Tissue-Based Therapy (Cell Therapy) 01/2022